NCT00581035已完成4 期
A Randomised Open Label Phase 4 Study to Evaluate the Safety and Immunogenicity of Concomitant Prevenar and Meningitec Compared to Prevenar Alone and Meningitec Alone When Used as Part of the Routine Vaccination Series in Healthy Infants
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 712 人开始时间: 2006年1月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 712
- 主要终点
- The pneumococcal and meningococcal responses achieved after the infant series
研究概览
简要总结
The purpose of this study is to evaluate the safety and immunogenicity of concomitant Prevenar and Meningitec compared to Prevenar alone and Meningitec alone when used as part of the routine vaccination series in healthy infants
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 42 Days 至 63 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy infants aged 6 to 9 weeks
排除标准
- 未提供
结局指标
主要结局
The pneumococcal and meningococcal responses achieved after the infant series
时间窗: 7 months
次要结局
- The pneumococcal and meningococcal responses achieved after the toddler dose(13 months)
研究者
相似试验
已完成
3 期
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)Neisseria MeningitidisBacterial InfectionsVirus DiseasesNCT01553279MCM Vaccines B.V.284
撤回
4 期
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)Mucopolysaccharidosis (MPS)Hunter SyndromeNCT05494593Takeda5
已完成
4 期
Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior TherapyHepatitis CNCT00266318Beth Israel Medical Center40
已完成
4 期
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.13-valent Pneumococcal VaccineImmunizationSafetyPremature BirthNCT01193335Pfizer200
已完成
1 期
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B VaccineVaccine-Preventable DiseasesHepatitis BNCT06147895CHA Vaccine Institute Co., Ltd.30